Behind Closed Doors: What Happens when Patients and Providers Talk about Prostate-Specific Antigen Screening?: Survey of the Effects of a Community-Based Intervention
- PMID: 22273170
- DOI: 10.2165/11312730-000000000-00000
Behind Closed Doors: What Happens when Patients and Providers Talk about Prostate-Specific Antigen Screening?: Survey of the Effects of a Community-Based Intervention
Abstract
Background: : Prostate-specific antigen (PSA) screening is controversial because of uncertainty about whether it reduces mortality and whether the potential benefits outweigh the harms. Given these uncertainties, many medical associations recommend using an informed decision-making (IDM) process for making decisions about PSA screening, so that men can make well informed decisions that reflect their values and preferences.
Objective: : The aim of this paper was to describe the communication exchange between men and their providers regarding PSA screening and the outcomes associated with having a discussion about screening from the patient perspective.
Methods: : We evaluated survey results obtained at baseline and approximately 12 months post-intervention. Baseline data collection took place in community-based organizations, and follow-up data were collected by mail. Men between 40 and 80 years of age who had not been diagnosed with prostate cancer were eligible for the study. We implemented a multicomponent, community-based intervention designed to help men make informed decisions about PSA screening. Primary outcome measures included characteristics of patient-provider discussions, screening behavior, feeling informed and satisfied, and patients' preferred and actual levels of involvement in screening decisions and concordance between the two.
Results: : Overall, 59% of men (220 of 373) had a discussion with a healthcare professional about the PSA screening test. Older men (those aged ≥50 years), Black men, and those who were married were more likely to talk to a provider. When a discussion did occur, two out of three men said that the discussion affected their decision making, and one-quarter changed their screening choice as a result. According to patients, there was apparent variation regarding the extent to which providers recommended the PSA test: 68% of providers recommended it and 3% did not recommend it. One in ten men said that the provider ordered the test without making a recommendation, while 15% of men said that providers did not make a recommendation and wanted the patient to decide.We found that the discussion between the patient and the provider about PSA screening was significantly associated with a greater probability of feeling informed and higher levels of satisfaction with the decision that was made. Most men preferred to be and were involved in the PSA screening decision collaboratively with their providers. When preferred and actual levels of involvement were concordant (i.e. men participated at their preferred level) and when men asked questions, men reported feeling more informed and satisfied about the screening decision.
Conclusion: : Ongoing education about the US Preventive Services Task Force (USPSTF) recommendation with respect to PSA screening should occur not only at the patient level but also at the provider level. More widespread adoption of the IDM process, which inherently involves building a patient's self-efficacy and skills needed to engage in it, is likely to take time.
Similar articles
-
Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey.J Cancer Educ. 2016 Dec;31(4):693-701. doi: 10.1007/s13187-015-0870-8. J Cancer Educ. 2016. PMID: 26498649 Free PMC article.
-
Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.JAMA. 2018 May 8;319(18):1901-1913. doi: 10.1001/jama.2018.3710. JAMA. 2018. PMID: 29801017
-
Promoting prostate-specific antigen informed decision-making. Evaluating two community-level interventions.Am J Prev Med. 2008 Aug;35(2):87-94. doi: 10.1016/j.amepre.2008.04.016. Am J Prev Med. 2008. PMID: 18617077 Clinical Trial.
-
Screening for prostate cancer: the current evidence and guidelines controversy.Can J Urol. 2011 Oct;18(5):5875-83. Can J Urol. 2011. PMID: 22018148 Review.
-
Informed decision making: what is its role in cancer screening?Cancer. 2004 Sep 1;101(5 Suppl):1214-28. doi: 10.1002/cncr.20512. Cancer. 2004. PMID: 15316908 Review.
Cited by
-
Primary care physicians' use of an informed decision-making process for prostate cancer screening.Ann Fam Med. 2013 Jan-Feb;11(1):67-74. doi: 10.1370/afm.1445. Ann Fam Med. 2013. PMID: 23319508 Free PMC article.
-
Physician Consultations, Prostate Cancer Knowledge, and PSA Screening of African American Men in the Era of Shared Decision-Making.Am J Mens Health. 2018 Jul;12(4):751-759. doi: 10.1177/1557988318763673. Epub 2018 Apr 16. Am J Mens Health. 2018. PMID: 29658371 Free PMC article.
-
Predictors of annual prostate-specific antigen (PSA) screening among black men: results from an urban community-based prostate cancer screening program.J Mens Health. 2021 Sep;17(4):78-83. doi: 10.31083/jomh.2021.081. Epub 2021 Sep 29. J Mens Health. 2021. PMID: 35096199 Free PMC article.
References
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous